Pharmacogenomics Microarray Applications Research Programme

Pharmacogenomics Microarray Applications Research Programme:

Accelerate Scientific Discoveries Through Collaboration

We are delighted to introduce the Pharmacogenomics Microarray Applications Research Programme (“Research Programme”), an exciting opportunity to collaborate with Thermo Fisher Scientific and transform scientific discoveries into real-world applications.

SPONSOR: The Sponsor of the Research Programme is Life Technologies LTD, Life Sciences Division, 3 Fountain Drive, Paisley PA4 NRF, UK, VAT GB180911219, an affiliate of Thermo Fisher Scientific Inc., (referred to herein as “Thermo Fisher Scientific”).

OBJECTIVE OF THE PROGRAMME: The objective of this Research Programme is to help academic and research scientists tackle their scientific questions by providing access to the Thermo Fisher Scientific microarray technology for pharmacogenomic testing. This is why we are launching this Research Programme offering the selected winner an opportunity to enter into a collaborative partnership with Thermo Fisher Scientific in the field of pharmacogenomic testing applications using microarray technology, thus gaining access to some of our most innovative products, namely Applied Biosystems Axiom PharmacoScan*, Applied Biosystems Axiom PharmacoFocus* or Applied Biosystems Axiom PangenomiX Plus*.

WHY PARTICIPATE: By participating in this programme, you will have access to Thermo Fisher Scientific's cutting-edge resources, expertise, and research tools. This collaboration will accelerate research and help unlock new possibilities in the field of pharmacogenomic testing using microarray applications.

HOW TO APPLY: To apply for the Research Programme, please follow the steps outlined below:

1. Visit the website thermofisher.com/microarray-pgx-research and fill in the Research Application Form.
2.  Fill out the Research Application Form with all the required information and additional proposal documents from the applicant. Ensure that you complete all the necessary fields accurately. Please note that the Application Form must be submitted in the English language.
3. Only electronic submissions made through the website thermofisher.com/microarray-pgx-research under the “Apply” submission area will be accepted.
4. Submit your proposal during open submission period: from 24 May to September 25 2025 before 12:01 AM CET European Time. Applications received after this deadline will not be considered.
5. Before applying, ensure that you are not prohibited from participating by the terms of your employment, law, regulation, or the policies or practices of your institution or employer.

By submitting the Application Form and for the scope of processing the application and the Research Programme, the Applicant understands and agrees that Thermo Fisher Scientific will process the relevant personal data according to the Thermo Fisher Scientific Privacy Notice available here: Thermo Fisher Scientific Privacy Notice | Thermo Fisher Scientific - RO

To this extent, the following personal data will be processed by Thermo Fisher Scientific according to its privacy policies and procedures: the Applicant’s name, institution, contact e-mail, biographical information, likeness and company information without compensation, except where prohibited by law and as otherwise provided herein.

Furthermore, through explicit consent, as described at the end of this document, Applicants may give permission, to Thermo Fisher Scientific to contact them about Thermo Fisher Scientific  products and services.

Please be aware that the Programme is subject to all applicable laws and may be void in certain jurisdictions where prohibited or where registration or bonding is required.

ELIGIBILITY: The Research Programme is open to doctoral and post-doctoral researchers in academic and research institutions located only in selected countries (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Luxembourg, Norway, Poland, Portugal, Slovakia, Spain, Switzerland, Sweden, The Netherlands, United Kingdom, Republic of Ireland., Estonia, Turkey, Slovenia, Croatia, Greece, Israel, Georgia, Moldova, Algeria, Tunisia, Kenya, Nigeria, Tanzania, Mauritius and South Africa). The person submitting the application (“Application”) is the applicant (“Applicant”) and is entering on behalf of their employer institution, which will be the research partner (“Research Partner”). To be eligible, Applicants must have obtained the necessary permission and authorisation from their employer or responsible supervisor to submit the Application.

Affiliates, subsidiaries, advertising, promotion, and fulfilment agencies of Sponsor, and employees, officers, and directors of Sponsor, together with their immediate family members and those living in the same household, are not eligible to participate. Government Officials[1]  located in eligible countries may not participate. Healthcare practitioners who prescribe prescription drugs and are licensed to provide patient health care in eligible countries may not participate.

Determination of eligibility is at Sponsor’s sole discretion.

SELECTION CRITERIA: We want to encourage pharmacogenetic researchers to address new scientific questions using our microarray technology: Applied Biosystems Axiom PharmacoScan, Applied Biosystems Axiom PharmacoFocus or Applied Biosystems Axiom PangenomiX Plus.

To be considered for selection, Applicants must have access to biological samples and access to other laboratory instrumentation, materials, reagents and laboratory space as necessary to perform the project. Applicant must confirm that it has obtained all necessary consents and approvals (including ethics approvals) required to conduct the Research Programme. Applicant must confirm that all samples will be fully anonymised such that no personal data (as defined in applicable data protection legislation) is shared with the Sponsor. Sponsor will not provide financial or other compensation for the Research Programme. The Research Partner is required to bear all expenses of the Research Programme including sample shipping fee.

Submissions will be evaluated based on scientific merit, approach and feasibility. The winning project will be selected by a qualified panel of judges (including medical and scientific affairs professionals) from the Sponsor based on the following weighted criteria:

• Potential impact to the field of pharmacogenomic research: How will scientific knowledge, technical capability or future clinical practice be improved by the findings? (1-5 points)
• Feasibility: Will the scientific proposal lead to new knowledge? (1-5 points)
• Applicant quality: Is there a research track record of the applicant and their supporting institution (1-5 points)
• Scientific merit: Is the use of Applied Biosystems Axiom PharmacoScan, Applied Biosystems Axiom PharmacoFocus or Applied Biosystems Axiom PangenomiX Plus appropriate to achieve goals (1-5 points)
• Novelty: Will the scientific proposal lead to new knowledge? (1-5 points)

The successful Applicant will be selected at Sponsor’s sole discretion, based solely on the evaluation described above. Judges’ decisions are final on all matters and shall not be subject to challenge or appeal. No information regarding judging or selection will be disclosed.

PROGRAMME CANCELLATION: There must be a minimum of ten (10) eligible submissions received by the deadline for this Research Programme to proceed to the stage where submissions will be reviewed by the panel of judges. If a minimum of ten (10) eligible submissions are not received by the deadline, this Research Programme will be cancelled. Should the Research Programme be cancelled, an announcement will be posted at address: thermofisher.com/ microarray-pgx-research and an email notification will be sent to each Applicant.

NOTIFICATION AND RESEARCH PARTNER’S OBLIGATIONS: The selected Research Partner will be notified before end of October 2025. The selected Research Partner will have the unique opportunity to enter into a Sponsored Collaboration Agreement with Thermo Fisher Scientific. The selected Research Partner will be required to execute and return the Sponsored Collaboration Agreement to the Sponsor within 30 calendar days following notification of their selection. If the Research Partner fails to do so, Sponsor may select an alternative Research Partner based on the selection criteria set forth above. The Research Partner should complete the project within 12 months of entering into the Sponsored Collaboration Agreement.

Sponsor is committed to strict compliance with all applicable laws and industry codes of conduct, including the MedTech Europe Code of Ethical Business Practice. The selection of the Research Partner is based solely on the criteria detailed above. The Research Partner agrees to cooperate with Sponsor in complying with its obligations under applicable laws, including providing information required for compliance with its reporting obligations (where applicable).

Except as otherwise agreed in the Sponsored Collaboration Agreement, the Research Partner agrees that it may use the data and/or materials produced by Sponsor in connection with the Microarray Research Services Laboratory solely for internal research purposes related to the Research Programme, not for use in humans or any diagnostic purpose, and in accordance with any Limited Use Label License (LULL) identified in the Sponsored Collaboration Agreement. The Research Partner further agrees that such data and/or materials produced by Sponsor in connection with the Microarray Research Services Laboratory shall not be transferred to or commercially used by or for any third party. Full terms and conditions applicable to MRSL services will be set out in the Sponsored Collaboration Agreement.

INTELLECTUAL PROPERTY: Ownership of the pre-existing underlying intellectual property of the Applicant remains the property of the Applicant subject to Sponsor's rights under these terms and conditions. By participating in the Research Programme, each Applicant grants to Sponsor a non-exclusive, worldwide, fully paid, royalty-free, perpetual, transferable, sub-licensable license to reprint, display, reproduce, perform, use and exhibit (including the right to make derivative works of) the Application and materials, and information submitted on and in connection with the Research Programme (“the Application Materials”) for the purpose of administering and promoting the Research Programme and for Sponsor's marketing and advertising purposes. Each Applicant hereby warrants and represents that: (i) their Application Materials are original and do not violate or infringe upon the copyrights, trademarks, rights of privacy, publicity or other intellectual property, or other rights of any person or entity, and do not violate any laws, rules or regulations; and (ii) if the Application Materials contain any material or elements that are not owned by Applicant and/or which are subject to the rights of third parties, Applicant has obtained, prior to submission of the Application Materials, any and all releases and consents necessary for Sponsor to be able to use them in the manner set forth in these terms and conditions  without additional compensation or liability to any party. Additional intellectual property terms will be set forth in the Sponsored Collaboration Agreement.

Publication authorship is the sole responsibility of the Research Partner and the research team. Sponsor reserves the right to review all publications of research results relating to the Research Programme and Sponsored Collaboration Agreement prior to submission to correct factual mistakes about Sponsor’s products and protect Sponsor’s proprietary information. Any such publication or other public communication must acknowledge the in-kind support provided by Sponsor and must be under open access.

The Applicant and Research Partner may be required to provide, jointly with Sponsor or individually, a testimonial, a webinar, a presentation, a publication or other information (“Collateral”) to promote the Research Programme, the research conducted pursuant to the Sponsored Collaboration Agreement, the Equipment or Sponsor as more specifically detailed in the Sponsored Collaboration Agreement. Sponsor shall have an unrestricted, irrevocable, worldwide license to reproduce, create derivatives of, distribute, perform, display, or perform a sound recording by means of digital audio of the Collateral, in any form, via any medium or channel.

The aforementioned terms constitute an integral part of the Sponsored Collaboration Agreement to be executed between the Sponsor and the selected Research Partner.

GENERAL RULES: . Return of any selection notification as undeliverable may result in disqualification and alternate determination. By participating in this Research Programme, Applicants agree to be bound by the terms and conditions set out herein and the decisions of Sponsor. Sponsor reserves the right at its sole discretion to disqualify any Applicant who tampers or attempts to tamper with the Application process or the operation of the Research Programme or website; violates the terms and conditions set out herein; or acts in an unsportsmanlike or disruptive manner, or with intent to annoy, abuse, threaten or harass any other person. Any attempt by any person to deliberately undermine the legitimate operation of the Research Programme may be a violation of criminal and civil law, and should such an attempt be made, Sponsor reserves the right to seek damages from any such person and participant to the fullest extent permitted by law. Sponsor's failure to enforce any provision herein shall not constitute a waiver of that provision. Sponsor and each of its respective affiliates, officers, directors, agents, and employees will have no liability or responsibility for any claim arising in connection with participation in this Research Programme or any award. Each Applicant assumes all liability for any injury or damage caused, or claimed to be caused, by participation in this Research Programme or use or redemption of any award.

RELEASE/LIMITATIONS OF LIABILITY: APPLICANT HEREBY INDEMNIFIES AND HOLDS SPONSOR HARMLESS FROM AND AGAINST ANY THIRD-PARTY CLAIM ARISING FROM OR IN CONENCTION WITH APPLICANT’S PARTICIPATION IN THE RESEARCH PROGRAMME OR THE APPLICATION. SPONSOR AND ITS AGENTS ARE NOT RESPONSIBLE FOR LOST, LATE, DAMAGED, MISDIRECTED, ILLEGIBLE, INCOMPLETE OR MUTILATED APPLICATIONS; OR FOR ANY TECHNICAL, HARDWARE, SOFTWARE OR TELEPHONE MALFUNCTIONS OF ANY KIND, LOST OR UNAVAILABLE NETWORK CONNECTIONS, DELAYS OR HUMAN ERRORS THAT OCCUR IN THE PROCESSING,TRANSMISSION OR RECEIPT OF APPLICATIONS; OR FOR INACCURATE TRANSCRIPTION OF APPLICATION INFORMATION; OR FOR APPLICATIONS THAT ARE STOLEN, MISDIRECTED, GARBLED, LOST OR DELAYED BY COMPUTER TRANSMISSIONS; OR IF FOR ANY REASON THE PROGRAMME IS NOT CAPABLE OF BEING CONDUCTED AS PLANNED, INCLUDING BUT NOT LIMITED TO INFECTION BY COMPUTER VIRUSES, BUGS, TAMPERING, UNAUTHORIZED INTERVENTION, FRAUD, TECHNICAL FAILURES OR OTHER CAUSES BEYOND THE CONTROL OF SPONSOR. SPONSOR RESERVES THE RIGHT AT ITS SOLE DISCRETION TO CANCEL, TERMINATE, MODIFY OR SUSPEND THE PROGRAMME. SPONSOR IS NOT RESPONSIBLE FOR FAILED, INCOMPLETE, INCORRECT OR INACCURATE APPLICATION INFORMATION, WHETHER CAUSED BY INTERNET USERS OR BY ANY OF THE EQUIPMENT OR PROGRAMMING ASSOCIATED WITH OR UTILISED IN THE RESEARCH PROGRAMME, OR BY ANY TECHNICAL OR HUMAN ERROR THAT MAY OCCUR IN THE PROCESSING OF THE APPLICATIONS IN THE RESEARCH PROGRAMME.

CHOICE OF LAW; VENUE: The Research Programme is governed by and construed in accordance with the laws of England, without giving effect to any choice or conflict of law provision.  Sponsor and Applicant irrevocably agree that the courts of England have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with these terms and/or the Research Programme, including non-contractual disputes.

IMPORTANT INFORMATION:

• No purchase is necessary to apply for the Research Programme.
• The Research Programme is subject to all applicable European laws and regulations.
• Government Officials located in eligible countries may not participate.
• Healthcare practitioners who prescribe prescription drugs and are licensed to provide patient health care in eligible countries may not participate.
• The Research Programme may be void in certain jurisdictions where prohibited or where registration or bonding is required.
•  Applicant is responsible for obtaining all necessary consents and approvals (including ethics approvals) required to conduct the Research Programme before submitting an Application. 

*For Research Use Only. Not for use in diagnostic procedures

[1] Government Official shall mean: (i) Any officer or employee of a government or any department, agency or instrument of a government; (ii) Any person acting in an official capacity for or on behalf of a government or any department, agency, or instrument of a government; (iii) Any officer or employee of a company or business, university or institution owned or funded in whole or part by a government; (iv) Any officer or employee of a public international organization such as the World Bank or United Nations, the European Union or the World Health Organization; (v) Any officer or employee of a political party or any person acting in an official capacity on behalf of a political party; and/or (vi) Any candidate for political office.